ClinicalTrials.gg
RecruitingNCT03209791Updated Nov 12, 2026

Ethanol Induces Skeletal Muscle Autophagy

An observational study in Alcoholic Liver Disease, sponsored by The Cleveland Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by The Cleveland Clinic · Observational

How we know

From the registry’s dates

  • Started May 2015; still recruiting 11 years 6 months later.
Updated Nov 12, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
40
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 23 studies in Liver Diseases, Alcoholic with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Liver Diseases, Alcoholic · United States.

Started
2015
the only one that year
Observational
7 of 23
4 open now
Registered
8th of 23
by date
Lead sponsor
4 of 23
The Cleveland Clinic

Among the 23 studies in Liver Diseases, Alcoholic with a site in United States, this one is the only one that started in 2015, is one of 7 observational ones, and was the 8th registered.

Liver Diseases, Alcoholic

74 studies on the registry are indexed under Liver Diseases, Alcoholic; 25 are open to participants now.

Browse Liver Diseases, Alcoholic studies →

Open to participants now

7 of the 23 studies in Liver Diseases, Alcoholic with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Liver Diseases, Alcoholic studies recruiting now, 7 (39%) set no upper age limit and 7 (39%) stop at 75 or younger; none take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Liver Diseases, Alcoholic with a site in United States, or all of them as a file.
02

Study summary

In this study we plan to demonstrate that ethanol induces skeletal muscle autophagy to degrade MAA adducts.

Read the detailed description

Hypothesis: Ethanol mediated modification of skeletal muscle proteins to form MAA adducts that in turn induce skeletal muscle autophagy.

Patients with alcoholic steatosis, hepatitis and cirrhosis (n=10 each) will be recruited from the liver transplant nutrition clinic or the hepatology inpatient service and their body composition quantified using anthropometry, bioelectrical impedance analysis, CT image analysis and DEXA if available.

Control Subjects. Controls will be recruited by advertisement. All control subjects will have a normal clinical history, physical examination, and screening chemistries. They will not have any significant medical conditions requiring the use of medications. Their nutritional status within 20% of normal as defined by ideal body weight.

03

Conditions studied

  • Alcoholic Liver Disease
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Histologically characterized patients with alcoholic steatosis, hepatitis and cirrhosis (n=10 each) will be recruited from the liver transplant nutrition clinic or the hepatology inpatient service and their body composition quantified using protocols already established by the PI.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Alcoholic liver disease:

  • clinical, biochemical, imaging criteria and liver where available
  • Age 18 - 65 years old

Controls:

  • Serum liver transaminases (i.e. and AST) 40 IU/L
  • Normal liver ultrasound
  • Age 18 - 65 years old

Exclusion criteria

Exclusion Criteria:

For both groups - alcoholic liver disease and controls:

  • Poorly controlled diabetes mellitus (>9.5 g/dl)
  • Untreated Hyper- / hypo- thyroidism
  • Patients on dialysis, renal disease with serum creatinine 1.5 mg/dL
  • Active intravenous drug use
  • History of bowel surgery or gastric bypass surgery
  • Medications known to alter muscle protein metabolism (i.e. , tamoxifen, high-dose estrogen, testosterone or anabolic steroids)
  • disease, Advanced cardiac or pulmonary disease
  • Pregnancy
  • Coagulopathy- >1.4 and count \<80,000/ml.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • Alcoholic Steatosis

    This group will have 10 patients with alcoholic steatosis which is milder disease and muscle biopsies will be performed

    Other: Biopsies

  • Cirrhosis

    This group will consist of 10 patients with cirrhosis. We anticipate a 50% difference in these patients and the controls in the autophagy readouts and muscle biopsies will be performed

    Other: Biopsies

  • Steatohepatitis

    This group will have 10 patients with alcoholic steatohepatitis that have more severe necroinflammation in the liver but for a shorter duration of illness and muscle biopsies will be performed

    Other: Biopsies

  • controls

    This group will consist of 10 patients who are healthy and have no liver disease diagnosis and muscle biopsies will be performed

    Other: Biopsies

Interventions

  • OtherBiopsies

    Biopsy will be done on the Vastus Lateralis muscle in all groups

06

What researchers measure

Primary outcomes

  1. Skeletal Muscle Autophagy

    We will measure Malonyldialdehyde Acetaldehyde protein adducts to see skeletal muscle proteolysis during a one time muscle biopsy

    Time frame: 4 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2015 (actual). Primary completion is estimated for Jun 2029, 169 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jun 2027 → Jun 2029 and completion Dec 2027 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2017
First posted
Jul 6, 2017
StartActual
May 18, 2015
Primary completionEst.
Jun 30, 2029was Jun 2027
CompletionEst.
Dec 31, 2029was Dec 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 30, 2027→Jun 30, 2029
Nov 12, 2026
Study completion
Dec 31, 2027→Dec 31, 2029
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Jun 30, 2027→Jun 30, 2029
    Study completion Dec 31, 2027→Dec 31, 2029
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03209791
Responsible party
Srinivasan Dasarathy (Staff Physician, The Cleveland Clinic) — Principal investigator
First posted
Jul 6, 2017
Start date
May 18, 2015
Primary completion
Jun 30, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Revathi Penumatsa, MPH
Contact
penumar@ccf.org
2164450688
Annette Bellar, MSLA
Contact
bellara@ccf.org
2166365247
Srinivasan Dasarathy, MD
principal investigator · The Cleveland Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion